Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Effect of Dexmedetomidine in Spinal Fusion
NCT02854904Phase 3Unknown
- Sponsor
- Rede SARAH de Hospitais de Reabilitação
- Start
- Aug 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in osteoarthritis of the spine (OA), spondylolysis and spondylolisthesis comparing Dexmedetomidine with Placebo (2 arms). Primary endpoints: Interleukin 1-beta at 48 hours, Interleukin 6 at 48 hours and 6 more. Status: unknown.
02
Drugs
dexmedetomidine
03
Conditions
osteoarthritis of the spine (OA)spondylolysisspondylolisthesis
Beyond the preview
Go deeper on NCT02854904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02854904.